GleamWall
中文EN

ALXO ALX ONCOLOGY HOLDINGS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1810182 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.4%
TTM EPS YoY56.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-94.4%
ROA-67.9%
ROIC (approx.)-99.6%
Asset turnover—

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.08x
Current ratio8.04x
Interest coverage-67.78x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$77.00M$116.37M
SG&A expense$23.85M$26.09M
Operating income-$104.02M-$142.47M
Interest expense$1.60M$1.73M
Pretax income-$101.69M-$134.85M
Income tax$0$0
Net income-$101.69M-$134.85M
EBITDA-$103.31M-$141.59M
EPS (basic)-1.90-2.58
EPS (diluted)-1.90-2.58
Weighted avg. shares (diluted)53.66M52.17M
Balance sheet
Cash & equivalents$16.37M$17.63M
Short-term investments$28.42M$110.19M
Current assets$50.73M$134.35M
PP&E, net$1.20M$2.90M
Total assets$59.05M$147.78M
Current liabilities$24.55M$18.50M
Short-term debt$5.22M$435,000
Long-term debt$4.53M$9.47M
Total debt$9.75M$9.90M
Total liabilities$33.06M$34.16M
Shareholders' equity$25.98M$113.62M
Net debt-$6.62M-$7.73M
Shares outstanding54.39M53.05M
Cash flow statement
Operating cash flow-$84.14M-$121.91M
Capital expenditure$212,000$447,000
Free cash flow-$84.35M-$122.36M
Investing cash flow$82.59M$86.26M
Financing cash flow$362,000$30.82M
Depreciation & amortization$706,000$872,000
Stock-based compensation$12.58M$27.09M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.